Opinion

Video

Staging and Treatment Decisions for Kidney Cancer

Author(s):

Neal Shore, MD, FACS,Brian M. Shuch, MD

Brian Shuch, MD, and Neal Shore, MD, FACS, discuss the staging and treatment of kidney cancer, including when to biopsy and how often to do follow-up imaging.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Jaleh Fallah, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Rasi - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Related Content
Cellular structures show link with survival outcomes in ccRCC
January 2nd 2025

Cellular structures show link with survival outcomes in ccRCC

Hannah Clarke
Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.
Top 10 kidney cancer stories in 2024
December 29th 2024

Top 10 kidney cancer stories in 2024

Hannah Clarke
As the year comes to a close, we revisit some of this year’s top content on the management of renal cancer.
First patient dosed in phase 1 trial of ADI-270 in ccRCC
December 19th 2024

First patient dosed in phase 1 trial of ADI-270 in ccRCC

Hannah Clarke
Initial data from the trial are expected to be released in the first half of 2025.
Belzutifan nears EU approval for advanced renal cell carcinoma
December 13th 2024

Belzutifan nears EU approval for advanced renal cell carcinoma

Hannah Clarke
A final decision on marketing authorization is anticipated for Q1 of 2025.
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
ALLO-316 shows encouraging CAR activity in advanced ccRCC
November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
© 2025 MJH Life Sciences

All rights reserved.